2020-11-12T08:56:10-06:00 2019-12-31 131655065 LUTZ AND CARR CPAS LLP 551 FIFTH AVENUE SUITE 400 NEW YORK NY 10176 990 2019-01-01 582492929 LUPUS RESEARCH ALLIANCE INC LUPU 2122182840 275 MADISON AVE 10TH FLOOR NEW YORK NY 10016 DEBRA ROSE CHIEF FIN. AND ADMIN. OFFICER 2122182840 2020-11-11 1 LAUREN CRESCI P01268493 2126972299 38.142.140.186 2020-11-11 16:18:36 ES P C6B84DD1F518B96753207BD5099AA33ACBC10C80 A75ECF90F4EA679C298DF903E96775B34A8C9CB0 2019 2021-01-29 14:40:06Z KENNETH M FARBER 275 MADISON AVE 10TH FLOOR NEW YORK NY 10016 30394667 0 X LUPUSRESEARCH.ORG X 1999 NY TO SUPPORT RESEARCH TO PREVENT, TREAT AND CURE LUPUS. 21 21 52 500 0 0 15396535 17673622 1334475 1236449 2296486 2148621 0 0 19027496 21058692 11290811 15505548 0 0 4888001 5172935 49000 49000 3029588 6635816 6083559 22863628 26811042 -3836132 -5752350 65079955 71431718 23818659 26661517 41261296 44770201 X THE LUPUS RESEARCH ALLIANCE LEADS THE WORLD IN TRANSFORMING THE LIVES OF PEOPLE AFFECTED WITH LUPUS BY USING THE POWER OF SCIENCE TO DRIVE NEW TREATMENTS, PREVENT DISEASE PROGRESSION, AND FIND A CURE. 0 0 11776654 10878438 RESEARCH:THE LUPUS RESEARCH ALLIANCE IS THE LARGEST NON-GOVERNMENTAL, NON-PROFIT FUNDER OF LUPUS RESEARCH WORLDWIDE. THE ORGANIZATION AIMS TO TRANSFORM TREATMENT WHILE ADVANCING TOWARD A CURE BY FUNDING THE MOST INNOVATIVE LUPUS RESEARCH, FOSTERING DIVERSE SCIENTIFIC TALENT, AND DRIVING DISCOVERY TOWARD BETTER DIAGNOSTICS, IMPROVED TREATMENTS AND ULTIMATELY A CURE FOR LUPUS. THE ORGANIZATION'S RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD ARE COMPRISED OF TOP SCIENTIFIC EXPERTS WHO WORK WITH STAFF TO STRATEGICALLY GUIDE AND DRIVE THE RESEARCH FUNDING AGENDA. SINCE ITS INCEPTION, THE LUPUS RESEARCH ALLIANCE HAS COMMITTED OVER $202 MILLION TO FUND LUPUS RESEARCH PROJECTS. IN 2019 ALONE, NEARLY $11 MILLION WAS AWARDED IN GRANTS FOR HIGHLY INNOVATIVE PROJECTS WITH THE POTENTIAL TO IMPROVE TREATMENT AS WELL AS UNDERSTAND THE CAUSES OF LUPUS THAT CAN LEAD TO A CURE: 1) A NEW INVESTIGATOR INITIATED CLINICAL TRIAL AWARD WAS MADE IN 2019 FOR OVER $2.5 MILLION OVER THREE YEARS THAT WILL EVALUATE THE EFFICACY OF ACE INHIBITORS IN COGNITIVE IMPAIRMENT ASSOCIATED WITH SLE. 2) 6 TARGET IDENTIFICATION IN LUPUS (TIL) THREE-YEAR GRANTS WITH A FOCUS OF IDENTIFYING NEW DRUG TARGETS AND HELPING FACILITATE EXPLORATION OF DRUG DEVELOPMENT WITH A TOTAL NEARLY $3.6 MILLION OVER THREE YEARS; 3) 6 NOVEL RESEARCH PROGRAM GRANTS THAT FOCUS ON INNOVATIVE EARLY-STAGE FUNDAMENTAL RESEARCH THAT ILLUMINATE THE DISEASE MECHANISM; AWARDED $1.8 MILLION OVER THREE YEARS;4) 2 DISTINGUISHED INNOVATOR AWARDS (DIA) FOCUS ON UNCOVERING THE UNDERLYING CAUSES OF LUPUS THAT CAN LEAD TO A CURE FOR $1 MILLION OVER TWO YEARS5) JOINT LUPUS RESEARCH ALLIANCE/PFIZER'S CENTERS FOR THERAPEUTIC INNOVATION (CTI) GRANTS WERE AWARDED FOR OVER $250,000 FOR ONE YEAR6) THE LUPUS INSIGHT PRIZE WAS AWARDED FOR $100,000. THIS AWARD RECOGNIZES AND FURTHERS WORK BY A LEADING RESEARCHER WHO HAS MADE A MAJOR CONTRIBUTION TO THE FIELD.7) THE LUPUS RESEARCH ALLIANCE SUPPORTED THE WORK OF THE LUPUS NEPHRITIS TRIALS NETWORK WITH A $200,000 AWARD - SUPPORTING COLLABORATIONS TO IDENTIFY AND VALIDATE THERAPEUTIC TARGETS FOR LUPUS NEPHRITIS.8) IN ADDITION, NEARLY $400,000 WAS FUNDED ON A STRATEGICALLY FOCUSED NON-PEER REVIEWED EFFORT TO HELP IDENTIFY WHERE LUPUS PATIENTS ARE IN THE US.THE LUPUS RESEARCH ALLIANCE'S UNIQUE FUNDING MODEL SUPPORTS PROMISING RESEARCH EFFORTS WITH THE GOAL OF IMPROVING THE LIVES OF PEOPLE WITH LUPUS IN THE NEAR FUTURE. THROUGH A COMPETITIVE PEER-REVIEW PROCESS PROJECTS BY THE LUPUS RESEARCH ALLIANCE AIM TO TRANSLATE RESULTS FROM THE RESEARCH BENCH TO THE BEDSIDE AS QUICKLY AS POSSIBLE. BECAUSE THE LUPUS RESEARCH ALLIANCE BOARD OF DIRECTORS FUNDS THE ADMINISTRATIVE AND FUNDRAISING EXPENSES, 100% OF ALL OTHER CONTRIBUTIONS GOES TO SUPPORT THE LUPUS RESEARCH ALLIANCE'S LUPUS RESEARCH PROGRAMS. 8906496 4625282 1236449 SCIENTIFIC PROGRAMS:2019 WAS A YEAR OF CONSIDERABLE ACTIVITY WITHIN LUPUS RESEARCH ALLIANCE'S (LRA) SCIENTIFIC PROGRAM WITH THE IMPLEMENTATION OF LRA'S SCIENTIFIC STRATEGIC PLAN FOCUSING ON HETEROGENEITY. THE LUPUS RESEARCH ALLIANCE ENCOURAGES CROSS-SECTOR AND CROSS-DISCIPLINE PARTNERSHIPS TO FOSTER THE MOST INNOVATIVE AND PRODUCTIVE RESEARCH ENVIRONMENT. IN 2019, COLLABORATIVE MEETINGS WERE FUNDED BY THE LUPUS RESEARCH ALLIANCE WHERE RESEARCHERS WERE ENCOURAGED TO EXCHANGE IDEAS AND HELP THE LUPUS RESEARCH ALLIANCE TARGET NEW RESEARCH OPPORTUNITIES. THIS INCLUDED THE: ANNUAL FORUM FOR DISCOVERY WHERE FUNDED SCIENTISTS AND GUESTS SHARE THEIR PROGRESS; RESEARCH COMMITTEE MEETINGS WHERE MEMBERS OF OUR BOARD OF DIRECTORS AS WELL AS TOP-LEVEL RESEARCHERS DISCUSSED OUR PORTFOLIO AND UPCOMING STRATEGIC STEPS; SCIENTIFIC ADVISORY BOARD MEETINGS WHERE OUR ADVISORS REVIEW GRANT APPLICATION SUBMISSIONS AND DISCUSS FUTURE OVERALL RESEARCH STRATEGY FOR THE ORGANIZATION; LUPUS INDUSTRY COUNCIL MEETINGS WHERE INDUSTRY FOCUSES ON SOLVING SHARED OBSTACLES TO CLINICAL TRIALS; PATIENT RESEARCH AND ADVOCACY MEETINGS THAT ENGAGE THE LUPUS COMMUNITY IN UNDERSTANDING, PARTICIPATING IN AND ADVOCATING FOR RESEARCH FUNDING; AND LUPUS CLINICAL INVESTIGATORS NETWORK (LUCIN) MEETINGS WHERE TOP RESEARCHERS DISCUSS THE DESIGN AND PROGRESS FOR LUPUS CLINICAL TRIALS. THE LUPUS RESEARCH ALLIANCE FOUNDED LUPUS THERAPEUTICS, LLC AS AN AFFILIATE OF THE LRA IN 2018 TO RUN LUCIN TO ADVANCE CLINICAL TRIALS AND FACILITATE THE DEVELOPMENT OF MUCH NEEDED NEW LUPUS TREATMENTS. THE LUPUS RESEARCH ALLIANCE PROVIDED NEARLY $4.5 MILLION IN GRANTS TO TOP ACADEMIC CENTERS TO FOSTER CLINICAL TRIAL PARTICIPATION IN LUCIN. LUPUS THERAPEUTICS (LT) CONTINUES TO HAVE A DIVERSE PORTFOLIO OF ONGOING CLINICAL TRIALS WITHIN LUCIN AND HAS COMPLETED ENROLLMENT MILESTONES FOR FIVE CLINICAL TRIALS AND REPORTED RESULTS FOR ONE TRIAL. MOREOVER, LT HAS A HEALTHY PIPELINE OF NEW BUSINESS DEVELOPMENT DISCUSSIONS WITH INDUSTRY RELATED TO PERFORMING ADVISORY SERVICES AND/OR CONDUCTING PROSPECTIVE CLINICAL TRIALS WITHIN THE NETWORK. IN 2019, THERE WERE ELEVEN ACTIVE STUDIES MANAGED VIA LUPUS THERAPEUTICS IN CONJUNCTION WITH THE LUCIN NETWORK WITH OBJECTIVES RANGING FROM;- EVALUATING THE SAFETY AND EFFICACY OF BRAND-NEW THERAPEUTICS FROM 6 DIFFERENT INDUSTRY PARTNERS- EVALUATING THE BENEFITS OF USING TIMED-RELEASED PREDNISONE - USING MRI TECHNOLOGY TO ASSESS LUPUS NEPHRITIS - TESTING THE BENEFITS OF KRILL OIL AS A MEDICAL FOOD- TESTING A SMARTPHONE APP THAT ALLOWS LUPUS PATIENTS TO REPORT SYMPTOMS IN REAL TIME AND PROVIDE MORE INFORMATION TO THEIR DOCTORS MORE EASILY. THE LUPUS RESEARCH ALLIANCE'S FORUM FOR DISCOVERY WAS A THREE DAY MEETING WITH OVER 120 DEDICATED RESEARCH SCIENTISTS, PHARMACEUTICAL INDUSTRY REPRESENTATIVES, AND LUPUS RESEARCH ALLIANCE ADVOCATES AND PARTNERS FOCUSED ENTIRELY ON LUPUS RESEARCH FOR THE THREE DAYS AT THIS ANNUAL SCIENTIFIC CONFERENCE. ALL LRA- FUNDED RESEARCHERS WERE GIVEN THE OPPORTUNITY TO PRESENT BY POSTER OR PRESENTATION THEIR MOST UP-TO-DATE RESEARCH, WHILE THE RICH DISCUSSIONS SERVED AS AN INCUBATOR TO SPARK IDEAS FOR NEW RESEARCH DIRECTIONS. IN ADDITION TO THE MANY EXCITING ADVANCES SHARED, ATTENDEES RETURNED TO THEIR LABS INSPIRED BY CRITICAL INSIGHTS FROM THE DISTINGUISHED KEYNOTE SPEAKERS. 846235 1828 PUBLIC POLICY:THE MAIN GOALS OF THE LUPUS RESEARCH ALLIANCE PUBLIC POLICY PROGRAM ARE TO: EDUCATE MEMBERS OF CONGRESS ABOUT ISSUES OF PRIORITY TO THE LUPUS COMMUNITY; INCREASE FEDERAL FUNDING FOR LUPUS RESEARCH BY INCREASING OVERALL NATIONAL INSTITUTES OF HEALTH (NIH) FUNDS, AND SECURE ADDITIONAL FUNDING FOR LUPUS RESEARCH THROUGH OTHER KEY FEDERAL AGENCIES INCLUDING THE VETERANS ADMINISTRATION AND DEPARTMENT OF DEFENSE (DOD). VOLUNTEERS ACROSS THE COUNTRY HELP AMPLIFY THESE OUTREACH EFFORTS.THROUGH THE LUPUS RESEARCH ALLIANCE ONGOING PUBLIC POLICY PROGRAM EFFORTS, SIGNIFICANT FUNDING FOR LUPUS RESEARCH HAS BEEN OBTAINED UNDER THE DEPARTMENT OF DEFENSE (DOD) CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS (CDMRP) OPERATED BY THE ARMY MEDICAL RESEARCH AND MATERIEL COMMAND. FIRST, THE LUPUS RESEARCH ALLIANCE WAS RESPONSIBLE FOR PERSUADING CONGRESS TO INCLUDE LUPUS IN ITS LIST OF DESIGNATED DISEASES ELIGIBLE FOR FUNDING OVER THE PAST TEN YEARS IN THE PEER REVIEWED MEDICAL PROGRAM. MOST RECENTLY, LUPUS RESEARCH ALLIANCE ADVOCACY SUCCEEDED IN THE ESTABLISHMENT IN 2017 OF THE LUPUS RESEARCH PROGRAM UNDER THE CDMRP. OVER THE PROGRAM'S FIRST THREE YEARS, $5 MILLION WAS EARMARKED EACH YEAR SPECIFICALLY FOR LUPUS; THROUGH THE LUPUS RESEARCH ALLIANCE'S CONTINUED EFFORTS THIS AMOUNT WAS INCREASED TO $10M IN THE DEFENSE HEALTH PROGRAM IN THE FY 2020 DEFENSE APPROPRIATIONS BILL AND IS AT $10M IN THE HOUSE DEFENSE APPROPRIATIONS BILL.IN 2017, THE LUPUS PATIENT-FOCUSED DRUG DEVELOPMENT (PFDD) INITIATIVE WAS LAUNCHED TO BRING THE VOICE OF THE PATIENT TO DRUG DEVELOPMENT. THIS COLLABORATIVE EFFORT WITH THE LUPUS AND ALLIED DISEASES ASSOCIATION (LADA) AND LUPUS FOUNDATION OF AMERICA (LFA) WAS DESIGNED TO PROVIDE THE FOOD AND DRUG ADMINISTRATION (FDA) WITH PERSPECTIVES FROM PEOPLE WITH LUPUS, ADVOCATES AND CAREGIVERS TO HELP INFORM THE FDA'S DECISIONS AND OVERSIGHT DURING THE DRUG DEVELOPMENT AND REVIEW PROCESSES. A REPORT WAS SENT TO THE FDA IN SPRING 2018. THE LRA CONTINUES TO WORK TO BRING THE VOICE OF THE PATIENT TO THE DRUG REVIEW PROCESS BY RESPONDING TO RELEVANT CALLS FROM THE FDA FOR COMMENTS. ONGOING ADVOCACY FOCUSES ON ENSURING LEGISLATION THAT SECURES THE FEDERAL FUNDING SUPPORT NECESSARY TO AFFORD INVESTIGATORS THE RESOURCES TO FOLLOW THROUGH WITH RESEARCH DISCOVERIES THAT WILL IMPROVE TREATMENT OF LUPUS. EVERY YEAR, THE LRA BRINGS ADVOCATES FROM ACROSS THE COUNTRY TO WASHINGTON DC FOR A DAY OF ADVOCACY TRAINING AND PRE-SCHEDULED MEETINGS WITH LEGISLATORS. THE GOAL IS TO INCREASE AWARENESS OF LUPUS AND THE IMPACT IT HAS ON PEOPLES' DAILY LIVES TO MEMBERS OF CONGRESS AND TO REQUEST THEIR SUPPORT FOR INCREASED FUNDING FOR LUPUS RESEARCH FROM FEDERAL PROGRAMS. TOMORROW'S ADVANCES DEPEND ON TODAY'S INVESTMENTS IN NIH RESEARCH. 21529385 1 1 0 1 0 0 0 0 0 1 1 0 0 0 1 0 0 1 0 0 1 1 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 62 0 1 52 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 21 21 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT FL GA HI IL KS KY ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN VA WA WV WI X X X DEBRA ROSE 6468846000 275 MADISON AVE 10 FLOOR NEW YORK NY 10016 IRA AKSELRAD CO-CHAIR 1.00 X X 0 0 0 RICHARD K DESCHERER CO-CHAIR 1.00 X X 0 0 0 JOSEPH MAURIELLO TREASURER 1.00 X X 0 0 0 BRENDA BLACKMON SECRETARY 1.00 X X 0 0 0 NEIL J BURMEISTER DIRECTOR 1.00 X 0 0 0 JEROME CHAZEN DIRECTOR 1.00 X 0 0 0 THOMAS O DANIEL DIRECTOR 1.00 X 0 0 0 JENNIE DESCHERER DIRECTOR 1.00 X 0 0 0 KATIE DRISCOLL DIRECTOR 1.00 X 0 0 0 SIR MARC FELDMANN DIRECTOR 1.00 X 0 0 0 MOTI FERDER DIRECTOR 1.00 X 0 0 0 JOE GERMANOTTA DIRECTOR 1.00 X 0 0 0 DAVID KIES DIRECTOR 1.00 X 0 0 0 DANIEL LAVECCHIA DIRECTOR 1.00 X 0 0 0 LOUIS LUCIDO DIRECTOR 1.00 X 0 0 0 MOLLY MCCABE DIRECTOR 1.00 X 0 0 0 NADEEM MEGHJI DIRECTOR 1.00 X 0 0 0 WILLIAM J MULVIHILL DIRECTOR 1.00 X 0 0 0 ROBERT SEDER MD DIRECTOR 1.00 X 0 0 0 DANIEL J WALLACE DIRECTOR 1.00 X 0 0 0 WILLIAM WOLFE DIRECTOR 1.00 X 0 0 0 CAROL WEISMAN DIRECTOR 1.00 X 0 0 0 SPENCER ZWICK DIRECTOR 1.00 X 0 0 0 KENNETH M FARBER CEO AND PRESIDENT 40.00 X 416526 0 72766 DEBRA ROSE CHIEF FINANCE OFFICER 40.00 X 195821 0 42642 ANDREA O'NEILL EXECUTIVE DIRECTOR 40.00 X 246253 0 47078 ALBERT ROY EXECUTIVE DIRECTOR, LUCIN 40.00 X 261724 0 62741 TEODORA STAEVA CHIEF SCIENTIFIC OFFICER 40.00 X 285631 0 57047 DIANE GROSS NATIONAL DIRECTOR OF ADVOC 40.00 X 130289 0 35290 MARGY MEISLIN EDITORIAL & PR DIRECTOR 40.00 X 127882 0 37177 DOREY NEILINGER SENIOR DIRECTOR OF PHILANT 40.00 X 165082 0 34323 DENISE PRIOR DIRECTOR OF COMMUNICATIONS 40.00 X 136357 0 19731 JONATHAN MARKS DIRECTOR OF CORPORATE 40.00 X 139123 0 62475 MARGARET P DOWD FORMER CO-CEO AND CO-PRESIDENT 40.00 X 203823 0 0 2308511 0 471270 11 1 1 0 AMPEL BIOSOLUTIONS LLC 250 WEST MAIN STREET SUITE 300 CHARLOTTESVILLE VA 22902 LUCIN CLINICAL TRIALS 325051 KIM KAISER & ASSOCIATES LLC 151 CENTRE AVE 1A NEW ROCHELLE NY 10805 PHARMA RELATIONS CONSULTANT 265585 KDH RESEACH AND COMMUNICATION INC 1175 PEACH TREE STREET NE ATLANTA GA 30361 PATIENT ENGAGEMENT CONSULTANTS 140479 CAVAROCCHI RUSCIA DENNIS & ASSOCIATES LL 600 MARLAND AVE SW SUITE 835 W WASHINGTON DC 20024 PUBLIC POLICY CONSULTANTS 102027 4 5355038 12318584 607005 17673622 LUCIN CONSULTING REVENUE 900099 1236449 1236449 1236449 1445946 1445946 9522480 8819805 702675 702675 702675 516170 5355038 516170 0 21058692 1236449 0 2148621 13609455 13609455 1828 1828 1894265 1894265 1612177 778927 361217 472033 2615038 1114639 603948 896451 177941 75962 38809 63170 502236 217956 115605 168675 265543 118367 60581 86595 150000 150000 79683 73312 5396 975 65399 65399 104186 104186 49000 49000 122792 122792 1041750 705958 156176 179616 115567 43339 54124 18104 514570 255833 198927 59810 1087395 549844 221269 316282 440447 292646 47496 100305 829731 751222 62651 15858 172125 76726 39269 56130 63877 39018 10233 14626 CLINICAL STUDIES 512086 512086 PRINTING & PUBLICATIONS 229776 48773 27194 153809 WALKATHON PROMOTIONAL E 216339 216339 DATA PROCESSING 106851 27331 18926 60594 230985 87712 42057 101216 26811042 21529385 2252069 3029588 4086022 3724504 1120958 873961 4778785 2579649 157680 373770 168860 162892 1097598 603119 573771 494479 52069569 61719649 1514965 398731 609345 1104083 65079955 71431718 465895 438885 22572203 25422502 780561 800130 23818659 26661517 X 36803806 39293680 4457490 5476521 41261296 44770201 65079955 71431718 X -5752350 7845756 1415499 X 0 1 X 1 0 X 15274909 19101537 23693133 15396535 17673622 91139736 15274909 19101537 23693133 15396535 17673622 91139736 33190250 57949486 1817934 1227336 1314981 1336303 1445946 7142500 118 -440 204 -118 98282118 2815330 0.58960 0.56890 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 846235 846235 25964807 26811042 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 541256 776350 788377 846235 2952218 250000 250000 250000 250000 1000000 1500000 46122925 8404231 2713456 51813456 51742397 -2936193 2683279 46122925 45863827 8478913 2600343 51742397 44173045 4257605 2566823 45863827 48100254 -1498278 2428931 44173045 1.00000 0 0 424912 141550 283362 672686 461569 211117 494479 DEFERRED RENT 800130 800130 30031656 7845756 1250000 9095756 20935900 122792 122792 21058692 26522751 0 26522751 122792 165499 288291 26811042 PART V, LINE 4: BOARD DESIGNATED (QUASI) ENDOWMENT FUND INCOME TO BE USED FOR RESEARCH PROGRAM GRANTS. PRINCIPAL TO REMAIN INTACT UNLESS HIGH PRIORITY LUPUS RESEARCH PROJECTS NEED TO BE FUNDED THAT COULD NOT BE FUNDED OTHERWISE. PART XII, LINE 4B - OTHER ADJUSTMENTS: RETURN OF GRANTS & ADJUSTMENTS 165,499. PART PART XII, LINE 4B UNUSED PORTIONS OF GRANTS RETURNED TO LRA THAT WERE PAID IN PREVIOUS YEARS IN THE AMOUNT OF $5,499. THESE AMOUNTS ARE RECONCILING ITEMS BETWEEN THE REVENUE AND EXPENSES FROM THE AUDITED FINANCIAL STATEMENTS AND THOSE REPORTED ON FORM 990. 1 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS 1254265 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 GRANTS TO RECIPIENTS 640000 0 0 0 0 0 0 1894265 0 1894265 NORTH AMERICA LUPUS RESEARCH 80000 CHECK BOOK NORTH AMERICA LUPUS RESEARCH 80000 CHECK BOOK NORTH AMERICA LUPUS RESEARCH 80000 CHECK BOOK NORTH AMERICA LUPUS RESEARCH 80000 CHECK BOOK NORTH AMERICA LUPUS RESEARCH 80000 CHECK BOOK NORTH AMERICA LUPUS RESEARCH 80000 CHECK BOOK NORTH AMERICA LUPUS RESEARCH 80000 CHECK BOOK NORTH AMERICA LUPUS RESEARCH 80000 CHECK BOOK EAST ASIA AND THE PACIFIC LUPUS RESEARCH 307535 CHECK BOOK EAST ASIA AND THE PACIFIC LUPUS RESEARCH 946730 CHECK BOOK 5 5 0 0 0 0 0 0 PART I, LINE 2: PRE AWARD AND APPLICATION PHASE: BEFORE A GRANT IS AWARDED, THE SPONSORING INSTITUTION (SI) MUST AGREE TO THE TERMS AND CONDITIONS OUTLINED IN THE LUPUS RESEARCH ALLIANCE (LRA)'S POLICY STATEMENT FOR RESEARCH GRANTS THAT INCLUDE: -CONFIRMATION BY THE PRINCIPAL INVESTIGATOR (PI) AND THE SI THAT FUNDS WILL ONLY BE USED AS DESCRIBED IN THE APPLICATION SUBMITTED AND APPROVED FOR FUNDING. -AGREE THAT PI AND SI ARE BOTH RESPONSIBLE FOR INSURING THAT ALL RESEARCH ACTIVITIES ARE CONDUCTED IN A SAFE, RESPONSIBLE AND ETHICAL MANNER. THEY MUST KEEP UPDATED APPROVAL FROM THE SI'S INSTITUTIONAL REVIEW BOARD AND ANIMAL CARE AND USE COMMITTEE THOUGHT OUT THE PROJECT PERIOD. -AGREE TO GET APPROVAL FROM THE LRA IF THERE NEEDS TO BE A SIGNIFICANT CHANGE TO THE BUDGET AS SUBMITTED. -AGREE TO GET APPROVAL FROM THE LRA IF ADDITIONAL TIME IS NEEDED TO COMPLETE THE PROJECT WORK. -AGREE TO SUBMIT ALL DELIVERABLES AND REPORTS AS SCHEDULED: (A) ANNUAL PROGRESS REPORTS AND (B) ANNUAL FINANCIAL REPORTS ARE REQUIRED. -TRAVEL FUNDS PROVIDED AS PART OF THE PROJECT ARE EXPECTED TO BE USED TO ATTEND THE LRA'S ANNUAL MEETING FORUM FOR DISCOVERY. -CONFIRMATION THAT THERE IS NO OTHER ACTIVE OF PENDING SUPPORT FOR THE SPECIFIC PROJECT THAT IS THE SUBJECT OF THE GRANT. POST AWARD: THE PI AND A REPRESENTATIVE FROM THE SI MUST SUBMIT: A SIGNED LETTER OF ACCEPTANCE CONFIRMING THE FOLLOWING: A. PI'S WILLINGNESS TO ADHERE TO THE TERMS OF THE BUDGET AS OUTLINED IN THE FUNDING LETTER. B. PI'S WILLINGNESS TO COMPLY WITH ALL OF THE CONDITIONS OUTLINED IN THE POLICY STATEMENT FOR RESEARCH GRANTS AND PATENT AND INTELLECTUAL PROPERTY POLICY. C. THERE IS NO OVERLAPPING SOURCE OF SUPPORT FOR THE SPECIFIC PROJECT THAT IS THE SUBJECT OF THIS GRANT. OTHER FUNDING THAT MIGHT BE CONSTRUED AS OVERLAPPING, MUST BE EXPLAINED IN DETAIL. D. THE FOLLOWING STATEMENT SHOULD APPEAR AT THE CONCLUSION OF THE LETTER OF ACCEPTANCE, "I AGREE TO ACCEPT RESPONSIBILITY FOR THE SCIENTIFIC AND TECHNICAL CONDUCT OF THE RESEARCH PROJECT AND FOR THE PROVISION OF ALL PROGRESS REPORTS REQUIRED FROM INVESTIGATORS FUNDED BY A GRANT FROM THE LUPUS RESEARCH ALLIANCE." -IF AN EXTENSION IS AWARDED ADDITIONAL INTERIM PROGRESS REPORTS AND BUDGET RECONCILIATIONS ARE REQUIRED TO BE SUBMITTED. -AT THE END OF THE GRANT A FINAL PROGRESS REPORT AND BUDGET RECONCILIATION IS REQUIRED TO BE SUBMITTED, UNSPENT AMOUNTS ARE TO BE RETURNED TO THE LRA. -ALL SIS RECEIVE A PAYMENT AND DELIVERABLE SCHEDULE AND THE PROJECT IS MONITORED BY: O PERIODIC PROGRESS REPORTS O PERIODIC BUDGET RECONCILIATIONS -ALL PUBLICATIONS RELATED TO THE GRANT ARE TO BE SUBMITTED TO THE LRA -THE LRA MUST BE LISTED AS A FUNDER IN ANY PUBLISHED PAPERS AND VERBAL OR POSTER PRESENTATIONS -THE SI MUST SUBMIT A COPY OF THE IRS OR OTHER TAX GOVERNING INSTITUTION CONFIRMING THE TAX STATUS OF THE SI PART III ACCOUNTING METHOD: X X X X X 1 DS CONSULTING GROUP 845 THIRD AVENUE 6TH FLOOR NEW YORK NY 10022 SPECIAL EVENT CONSULTANT NY GALA 1 2982628 49000 2982628 2982628 49000 2982628 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX VT VA WA WV WI WY GALA CELEBRATION 2982628 2654211 328417 181157 147260 WALK-A-THONS 1361711 1331735 29976 29976 2 1526869 1369092 157777 157777 5871208 5355038 516170 181157 335013 516170 0 SCHEDULE G, PART I, LINE 2B, COLUMN (V) DS CONSULTING PLANNED AND MANAGED ALR'S GALA EVENT. CONTRACT AMOUNT FOR THE PERIOD COVERING 1/1/19 - 12/31/19 WAS $49,000 PLUS REIMBURSABLE EXPENSES. 1 ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 472209056 501(C)(3) 80000 BOOK LUPUS RESEARCH BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501(C)(3) 80000 BOOK LUPUS RESEARCH BRIGHAM AND WOMEN'S HOSPITAL 77 AVENUE LOUIS PASTEUR BOSTON MA 02115 042312909 501(C)(3) 777449 BOOK LUPUS RESEARCH BROAD INSTITUTE INC SEVEN CAMBRIDGE CENTER CAMBRIDGE MA 02142 263428781 501(C)(3) 13470 BOOK LUPUS RESEARCH CHILDREN'S HOSPITAL BOSTON 300 LONGWOOD AVENUE BOSTON MA 02115 042774441 501(C)(3) 195640 BOOK LUPUS RESEARCH COLUMBIA UNIVERSITY MEDICAL CENTER 154 HAVEN AVE 2ND FL NEW YORK NY 10032 133598093 501(C)(3) 122514 BOOK LUPUS RESEARCH EMORY UNIVERSITY 1762 CLIFTON RD NE ATLANTA GA 30322 580566256 501(C)(3) 246000 BOOK LUPUS RESEARCH HOSPITAL FOR SPECIAL SURGERY 535 E 70TH STREET NEW YORK NY 10021 131624135 501(C)(3) 104952 BOOK LUPUS RESEARCH LOYOLA UNIVERSITY OF CHICAGO 820 N MICHIGAN AVE CHICAGO IL 60611 361408475 501(C)(3) 300000 BOOK LUPUS RESEARCH MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)(3) 80000 BOOK LUPUS RESEARCH MAYO CLINIC 200 FIRST STREET SW ROCHESTER MN 55905 416011702 501(C)(3) 80000 BOOK LUPUS RESEARCH MEDICAL UNIVERSITY OF SOUTH CAROLINA 179 ASHLEY AVENUE CHARLESTON SC 29425 576028985 SECTION 115 - SC STA 90381 BOOK LUPUS RESEARCH NATIONAL MINORITY QUALITY FORUM INC 1201 15TH STREET NW SUITE 340 WASHINGTON DC 20005 311750942 501(C)(3) 379800 BOOK LUPUS RESEARCH NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVENUE NEW YORK NY 10016 135562308 501(C)(3) 100183 BOOK LUPUS RESEARCH NORTHWELL HEALTH - DIVISION OF RHEUMATOLOGY 972 BRUSH HOLLOW RD 5TH FL WESTBURY NY 11590 112673595 501(C)(3) 80000 BOOK LUPUS RESEARCH NORTHWESTERN UNIVERSITY 633 CLARK STREET EVANSTON IL 60208 362167818 501(C)(3) 380000 BOOK LUPUS RESEARCH OKLAHOMA MEDICAL RESEARCH FOUNDATION 825 NE 13TH STREET OKLAHOMA CITY OK 73104 730580274 501(C)(3) 380000 BOOK LUPUS RESEARCH PENNSYLVANIA STATE UNIVERSITY ONE OLD MAIN UNIVERSITY PARK PA 16802 246000376 501(C)(3) 96613 BOOK LUPUS RESEARCH REGENTS OF THE UNIVERSITY OF CALIFORNIA IRVINE 5171 CALIFORNIA AVENUE STE 150 IRVINE CA 92697 952226406 501(C)(3) 80000 BOOK LUPUS RESEARCH RUSH UNIVERSITY MEDICAL CENTER 1653 WEST CONGRESS PARKWAY CHICAGO IL 60612 362174823 501(C)(3) 80000 BOOK LUPUS RESEARCH ST JUDE CHILDREN'S HOSPITAL 262 DANNY THOMAS PL MEMPHIS TN 38105 620646012 501(C)(3) 580158 BOOK LUPUS RESEARCH STANFORD UNIVERSITY 3145 PORTER DRIVE PALO ALTO CA 94304 941156365 501(C)(3) 80000 BOOK LUPUS RESEARCH TEMPLE UNIVERSITY 1801 N BROAD STREET PHILADELPHIA PA 19122 231365971 501(C)(3) 90616 BOOK LUPUS RESEARCH THE CENTER FOR INFORMATION & STUDY ON CLINICAL RESARCH PARTICPATION 56 COMMERCIAL WHARF EAST BOSTON MA 02110 200588190 501(C)(3) 5000 BOOK LUPUS RESEARCH THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH 350 COMMUNITY DRIVE MANHASSET NY 11030 112673595 501(C)(3) 3107722 BOOK LUPUS RESEARCH THE METROHEALTH SYSTEM 2500 METROHEALTH DRIVE CLEVELAND OH 44109 346004382 SECTION 115 - OH STA 80000 BOOK LUPUS RESEARCH THE OHIO STATE UNIVERSITY 1960 KENNY ROAD COLUMBUS OH 43210 311702164 SECTION 115 - OH STA 80000 BOOK LUPUS RESEARCH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES 10920 WILSHIRE BLVD STE 620 LOS ANGELES CA 90024 956006143 501(C)(3) 179446 BOOK LUPUS RESEARCH THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC0934 LA JOLLA CA 92093 956006144 501(C)(3) 105000 BOOK LUPUS RESEARCH THE RESEARCH FOUNDATION OF SUNY 35 STATE STREET ALBANY NY 12201 141368361 501(C)(3) 80000 BOOK LUPUS RESEARCH THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE STE 501 CHICAGO IL 60637 362177139 501(C)(3) 80000 BOOK LUPUS RESEARCH THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 6000 FELDWOOD ROAD COLLEGE PARK GA 30349 566001393 501(C)(3) 183334 BOOK LUPUS RESEARCH TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET PHILADELPHIA PA 19104 231352685 501(C)(3) 637993 BOOK LUPUS RESEARCH UNIVERISTY OF SOUTHERN CALIFORNIA 1640 MARENGO STREET 7TH FL LOS ANGELES CA 90033 951642394 501(C)(3) 90377 BOOK LUPUS RESEARCH UNIVERSITY OF ALABAMA AT BIRMINGHAM 1530 3RD AVE S BIRMINGHAM AL 35294 636005396 501(C)(3) 672197 BOOK LUPUS RESEARCH UNIVERSITY OF CALIFORNIA SAN FRANCISCO 2200 UNIVERSITY HALL BERKELEY CA 94720 946036493 501(C)(3) 88932 BOOK LUPUS RESEARCH UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS 3100 MARINE ST 6TH FL BOULDER CO 80309 846000555 501(C)(3) 80000 BOOK LUPUS RESEARCH UNIVERSITY OF FLORIDA 207 TIGERT HALL GAINESVILLE FL 32611 596002052 FL STATE GOVERNMENT 86020 BOOK LUPUS RESEARCH UNIVERSITY OF HOUSTON 4800 CALHOUN ROAD HOUSTON TX 77004 746001399 501(C)(3) 10312 BOOK LUPUS RESEARCH UNIVERSITY OF MARYLAND BALTIMORE 620 W LEXINGON STREET 4TH FL BALTIMORE MD 21201 521830242 SECTION 115 - MD STA 80000 BOOK LUPUS RESEARCH UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER MA 01655 043167325 MA STATE GOVERNMENT 96742 BOOK LUPUS RESEARCH UNIVERSITY OF MIAMI 1320 S DIXIE HIGHWAY GABLES ONE TOWER 650 CORAL GABLES FL 33146 590624458 501(C)(3) 80000 BOOK LUPUS RESEARCH UNIVERSITY OF MICHIGAN 503 THOMPSON STREET ANN ARBOR MI 48109 386006309 501(C)(3) 972198 BOOK LUPUS RESEARCH UNIVERSITY OF MISSISSIPPI MEDICAL CENTER 2500 NORTH STATE STREET JACKSON MS 39216 646008520 501(C)(3) 90000 BOOK LUPUS RESEARCH UNIVERSITY OF NEBRASKA 987835 NEBRASKA MEDICAL CENTER OMAHA NE 68198 470049123 501(C)(3) 8932 BOOK LUPUS RESEARCH UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER AT FORT WORTH 3500 CAMP BOWIE BLVD FORT WORTH TX 76107 710986983 501(C)(3) 6020 BOOK LUPUS RESEARCH UNIVERSITY OF PITTSBURGH 123 UNIVERSITY PLACE PITTSBURGH PA 15213 250965591 501(C)(3) 97864 BOOK LUPUS RESEARCH UNIVERSITY OF ROCHESTER 518 HYLAN BUILDING ROCHESTER NY 14627 160743209 501(C)(3) 80000 BOOK LUPUS RESEARCH UNIVERSITY OF WASHINGTON 3917 UNIVERSITY WAY NE SEATTLE WA 98195 916001537 SECTION 115 - WA STA 86713 BOOK LUPUS RESEARCH UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 746000203 TX STATE GOVERNMENT 86567 BOOK LUPUS RESEARCH VANDERBILT UNIVERSITY MEDICAL CENTER 1211 MEDICAL CENTER DRIVE NASHVILLE TN 37232 352528741 501(C)(3) 1026730 BOOK LUPUS RESEARCH WAKE FOREST UNIVERSITY HEALTH SCIENCES MEDICAL CENTER BLVD WINSTONSALEM NC 27157 223849199 501(C)(3) 80000 BOOK LUPUS RESEARCH WALLACE RHEUMATIC STUDIES CENTER LLC 8737 BENVERLY BLVD STE 301 W HOLLYWOOD CA 90048 455434561 501(C)(3) 80000 BOOK LUPUS RESEARCH YAEL UNIVERSITY BOX 208239 NEW HAVEN CT 06520 060646973 501(C)(3) 93425 BOOK LUPUS RESEARCH UNIVERSITY OF TEXAS AT SAN ANTONIO 7703 FLOYS CURL DRIVE SAN ANTONIO TX 782293900 746000203 TX STATE GOVERNMENT 580155 BOOK LUPUS RESEARCH 46 9 PART I, LINE 2: PRE AWARD AND APPLICATION PHASE: BEFORE A GRANT IS AWARDED, THE SPONSORING INSTITUTION (SI) MUST AGREE TO THE TERMS AND CONDITIONS OUTLINED IN THE LUPUS RESEARCH ALLIANCE (LRA)'S POLICY STATEMENT FOR RESEARCH GRANTS THAT INCLUDE: -CONFIRMATION BY THE PRINCIPAL INVESTIGATOR (PI) AND THE SI THAT FUNDS WILL ONLY BE USED AS DESCRIBED IN THE APPLICATION SUBMITTED AND APPROVED FOR FUNDING. -AGREE THAT PI AND SI ARE BOTH RESPONSIBLE FOR INSURING THAT ALL RESEARCH ACTIVITIES ARE CONDUCTED IN A SAFE, RESPONSIBLE AND ETHICAL MANNER. THEY MUST KEEP UPDATED APPROVAL FROM THE SI'S INSTITUTIONAL REVIEW BOARD AND ANIMAL CARE AND USE COMMITTEE THOUGHT OUT THE PROJECT PERIOD. -AGREE TO GET APPROVAL FROM THE LRA IF THERE NEEDS TO BE A SIGNIFICANT CHANGE TO THE BUDGET AS SUBMITTED. -AGREE TO GET APPROVAL FROM THE LRA IF ADDITIONAL TIME IS NEEDED TO COMPLETE THE PROJECT WORK. -AGREE TO SUBMIT ALL DELIVERABLES AND REPORTS AS SCHEDULED: (A) ANNUAL PROGRESS REPORTS AND (B) ANNUAL FINANCIAL REPORTS ARE REQUIRED. -TRAVEL FUNDS PROVIDED AS PART OF THE PROJECT ARE EXPECTED TO BE USED TO ATTEND THE LRA'S ANNUAL MEETING FORUM FOR DISCOVERY. -CONFIRMATION THAT THERE IS NO OTHER ACTIVE OF PENDING SUPPORT FOR THE SPECIFIC PROJECT THAT IS THE SUBJECT OF THE GRANT. POST AWARD: THE PI AND A REPRESENTATIVE FROM THE SI MUST SUBMIT: A SIGNED LETTER OF ACCEPTANCE CONFIRMING THE FOLLOWING: A. PI'S WILLINGNESS TO ADHERE TO THE TERMS OF THE BUDGET AS OUTLINED IN THE FUNDING LETTER. B. PI'S WILLINGNESS TO COMPLY WITH ALL OF THE CONDITIONS OUTLINED IN THE POLICY STATEMENT FOR RESEARCH GRANTS AND PATENT AND INTELLECTUAL PROPERTY POLICY. C. THERE IS NO OVERLAPPING SOURCE OF SUPPORT FOR THE SPECIFIC PROJECT THAT IS THE SUBJECT OF THIS GRANT. OTHER FUNDING THAT MIGHT BE CONSTRUED AS OVERLAPPING, MUST BE EXPLAINED IN DETAIL. D. THE FOLLOWING STATEMENT SHOULD APPEAR AT THE CONCLUSION OF THE LETTER OF ACCEPTANCE, "I AGREE TO ACCEPT RESPONSIBILITY FOR THE SCIENTIFIC AND TECHNICAL CONDUCT OF THE RESEARCH PROJECT AND FOR THE PROVISION OF ALL PROGRESS REPORTS REQUIRED FROM INVESTIGATORS FUNDED BY A GRANT FROM THE LUPUS RESEARCH ALLIANCE." -IF AN EXTENSION IS AWARDED ADDITIONAL INTERIM PROGRESS REPORTS AND BUDGET RECONCILIATIONS ARE REQUIRED TO BE SUBMITTED. -AT THE END OF THE GRANT A FINAL PROGRESS REPORT AND BUDGET RECONCILIATION IS REQUIRED TO BE SUBMITTED, UNSPENT AMOUNTS ARE TO BE RETURNED TO THE LRA. -ALL SIS RECEIVE A PAYMENT AND DELIVERABLE SCHEDULE AND THE PROJECT IS MONITORED BY: 1 PERIODIC PROGRESS REPORTS 2 PERIODIC BUDGET RECONCILIATIONS -ALL PUBLICATIONS RELATED TO THE GRANT ARE TO BE SUBMITTED TO THE LRA -THE LRA MUST BE LISTED AS A FUNDER IN ANY PUBLISHED PAPERS AND VERBAL OR POSTER PRESENTATIONS -THE SI MUST SUBMIT A COPY OF THE IRS OR OTHER TAX GOVERNING INSTITUTION CONFIRMING THE TAX STATUS OF THE SI X X X X X 1 0 0 0 0 0 0 0 0 KENNETH M FARBER CEO AND PRESIDENT 360000 0 50000 0 6526 0 28000 0 44766 0 489292 0 0 0 DEBRA ROSE CHIEF FINANCE OFFICER 178605 0 15000 0 2216 0 21047 0 21595 0 238463 0 0 0 ANDREA O'NEILL EXECUTIVE DIRECTOR 204750 0 40000 0 1503 0 26733 0 20345 0 293331 0 0 0 ALBERT ROY EXECUTIVE DIRECTOR, LUCIN 220752 0 40000 0 972 0 20860 0 41881 0 324465 0 0 0 TEODORA STAEVA CHIEF SCIENTIFIC OFFICER 244359 0 40000 0 1272 0 22749 0 34298 0 342678 0 0 0 DIANE GROSS NATIONAL DIRECTOR OF ADVOC 127435 0 2000 0 854 0 13420 0 21870 0 165579 0 0 0 MARGY MEISLIN EDITORIAL & PR DIRECTOR 125000 0 1000 0 1882 0 12600 0 24577 0 165059 0 0 0 DOREY NEILINGER SENIOR DIRECTOR OF PHILANT 161029 0 0 0 4053 0 17713 0 16610 0 199405 0 0 0 DENISE PRIOR DIRECTOR OF COMMUNICATIONS 69436 0 0 0 66921 0 2381 0 17350 0 156088 0 0 0 JONATHAN MARKS DIRECTOR OF CORPORATE 135403 0 3000 0 720 0 15224 0 47251 0 201598 0 0 0 MARGARET P DOWD FORMER CO-CEO AND CO-PRESIDENT 203823 0 0 0 0 0 0 0 0 0 203823 0 0 0 PART I, LINE 4A DENISE PRIOR, HIGHLY COMPENSATED EMPLOYEE, RECIEVED $59,517 SEVERANCE PAYMENT IN 2019. X 7 113505 AVG STOCK VALUE X 1 493500 APPRAISED VALUE 0 1 1 PART I, LINE 32B: LRA HAS AN ACCOUNT WITH MORGAN STANLEY, WHICH LRA USES TO SELL THE CONTRIBUTIONS IT RECEIVES THOUGH STOCKS. LRA HIRED AN AGENT TO SELL A PROPERTY THAT WAS DONATED TO LRA FORM 990, PART VI, SECTION A, LINE 2 NEIL J. BURMEISTER (DIRECTOR) AND IRA AKSELRAD (DIRECTOR) HAVE A BUSINESS RELATIONSHIP. RICHARD K. DESCHERER (CO-CHAIR) AND JENNIE DESCHERER HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B AFTER PREPARATION BY OF FORM 990 BY LRA'S AUDITOR, LUTZ AND CARR, THE 990 IS REVIEWED BY THE LRA'S SENIOR OFFICERS, THE CHIEF FINANCE OFFICER AND THE PRESIDENT. THE FINANCE AND AUDIT COMMITTEE OF THE BOARD THEN MEETS TO REVIEW THE 990 BEFORE FILING AND APPROVES FOR FILING WITH ANY NOTED CHANGES. A DRAFT OF THE 990 IS THEN SENT OUT TO THE FULL BOARD FOR COMMENT PRIOR TO FILING WITH THE IRS. THE FINAL FORM 990 IS PRESENTED TO THE FULL BOARD AT THE SEPTEMBER MEETING. FORM 990, PART VI, SECTION B, LINE 12C THE GOVERNANCE COMMITTEE OF THE BOARD IS RESPONSIBLE FOR MONITORING CONFLICTS OF INTEREST. AN ANNUAL CONFLICT OF INTEREST DISCLOSURE FORM IS REQUIRED TO BE FILLED OUT EACH YEAR BY BOARD MEMBERS, OFFICERS AND KEY EMPLOYEES. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS ASSISTED THE BOARD IN FULFILLING ITS OVERSIGHT RESPONSIBILITIES RELATING TO THE COMPENSATION AND BENEFITS OF THE PRESIDENT AND OTHER EXECUTIVE OFFICERS; AND PROVIDED RECOMMENDATIONS REGARDING MANAGEMENT SUCCESSORS. ANNUALLY THE COMMITTEE REVIEWS AND RECOMMENDS TO THE BOARD THE SALARY FOR THE PRESIDENT AND OTHER OFFICERS/KEY EMPLOYEES. IN 2018, THE COMMITTEE REVIEWED AND APPROVED BASE SALARIES, ANNUAL MERIT ADJUSTMENTS AND BONUSES FOR ALL STAFF. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST AND ON GUIDESTAR.ORG FORM 990, PART XI, LINE 9: REFUND OF GRANTS 165,499. CANCELLED GRANTS 1,250,000. FORM 990, PART V, QUESTION 2A THE LRA CONTRACTS WITH TRINET AMBROSE, A PROFESSIONAL EMPLOYER ORGANIZATION (PEO), TO PROVIDE PAYROLL AND BENEFITS AS A CO-EMPLOYER WITH THE LRA. LRA PAYROLL AND BENEFITS ARE ADMINISTERED BY AMBROSE AS APPROVED BY LRA OFFICERS. LRA PAYROLL IS THEREFORE UNDER THE AMBROSE EIN: 13-3867443 AND W-2'S ARE PREPARED UNDER THAT EIN BY TRINET AMBROSE. LUPUS THERAPEUTICS LLC 2550 SOUTH CLARK SUITE 670 ARLINGTON VA 22202 823984908 LRA'S SCIENTIFIC PROGRAMS VA 1236449 YES